Business Wire

ONWARD Reports 2021 Full Year Financial and Operating Results


ONWARD Medical N.V. (Euronext: ONWD), the medical technology company creating innovative therapies to restore movement, independence, and health in people with spinal cord injury, today announces its annual financial and operating results for the year ended December 31, 2021. The Company also provides a business update for Q1 2022.

The company further announces the publication of its statutory annual accounts for the financial year ended December 31, 2021, prepared in accordance with International Financial Reporting Standards (IFRS-EU), as drawn up and approved by the Board and included in the Company's annual report (the Annual Report).

The full Annual Report is available on the Company’s website in the Investors section ( and the website of the Netherlands Authority for the Financial Markets (

The Company’s Financial and Operating highlights for 2021 include the following:

  • Awarded Breakthrough Device Designation from the US Food and Drug Administration (FDA) for the Company’s ARCIM Therapy focused on restoration of normal blood pressure and trunk control for people with spinal cord injury (SCI). This is the Company’s third such designation.
  • Completed enrollment in its Up-LIFT pivotal study in December, ahead of expectations and in less than 12 months despite COVID-related challenges. Up-LIFT is the first large-scale pivotal trial of non-invasive spinal cord stimulation technology.
  • Completed development of the initial generation of its ARCIM technology platform in preparation for first-in-human use of its IPG and Lead family, expected to occur in 2022 as part of the HeMon Study.
  • Raised EUR 30 million through a pre-initial public offering (IPO) convertible note financing.
  • Raised EUR 80 million in an IPO on Euronext Brussels and Euronext Amsterdam in October, believed to be the largest early-stage medtech IPO in European history.

The Company reported an Operating Loss of EUR 34.3 million for 2021 vs. EUR 20.0 million in 2020. The Company’s year-end balance for cash and cash equivalents increased to EUR 89.4 million on December 31, 2021 vs. EUR 6.4 million on December 31, 2020.

“Despite challenging conditions that impacted businesses worldwide, we executed strongly against our primary objectives in 2021”, said Dave Marver, CEO of ONWARD. “We demonstrated excellent progress in R&D by completing our implantable device platform, and in Clinical/Regulatory by completing enrollment in the Up-LIFT Study ahead of expectations and receiving our third Breakthrough Device Designation award from the FDA. Lastly, we successfully completed two important financings, including a large IPO that attracted a high-quality group of investors from the US, Europe, and across the world. We expect our strong cash position from these financings to provide runway through the end of 2024, but we will continue to explore options to raise even more capital and increase liquidity through financing activities.”

2021 Financial Summary

EUR millions



Total Grant Income



Total Operating Expenses



Science expenses



Research & Development expenses



Clinical & Regulatory expenses



Marketing & Market Access expenses



Patent Fees & Related expenses



Quality Assurance expenses



General & Administrative expenses



Operating Loss for the Period



Net Finance expense



Net Loss for the Period



Basic (and diluted) Earnings per Share (in EUR)



Cash position at the end of the year



Interest Bearing Loans






Grant Income
Grant income increased by EUR 0.6 million vs. 2020, totaling EUR 1.4 million in 2021 and driven primarily by proceeds from a DARPA grant that commenced in October 2020. ONWARD is part of a research consortium eligible to receive up to USD 36 million as part of the DARPA Bridging the Gap+ program.

Operating Expenses
Operating expenses increased by EUR 13.7 million vs. 2020, totaling EUR 30 million in 2021. The increase was driven primarily by a EUR 8.2 million increase in employee costs, with full-time equivalent (FTE) employees increasing from 55 in 2020 to 76.9 in 2021. EUR 2.4 million of the employee cost increase can be attributed to additional FTEs while EUR 5.8 million can be attributed to share-based payment expense due to accelerated vesting of the Company’s Employee Investment Plan on the date of the Company’s IPO.

Consulting services and other costs associated with research and development of the Company’s therapies increased by EUR 0.4 million vs. 2020. Activities to drive enrollment in the Company’s Up-LIFT pivotal trial and other clinical study related costs contributed to an increase of EUR 1.4 million vs. 2020. The Company also incurred an incremental EUR 0.4 million for marketing and market access activities in the US and Europe. The Company’s 2021 IPO and the incremental costs of operating as a public company added EUR 2.4 million not incurred in 2020. These costs include uncapitalized consulting and legal expenses relating to the IPO and assuring compliance with financial regulatory requirements.

Operating Loss for the Period
The Company’s Operating Loss for the period increased by EUR 13 million, driven by the increase in Operating Expenses.

Net Loss for the Period
The Company realized a Net Loss for the period of EUR 34.3 million vs. EUR 20 million in 2020. EUR 13.0 million of this increase can be attributed to the Operating Loss for the period. An additional EUR 1.2 million is due to an increase in the Company’s Net Finance Expense, driven primarily by an increase in Interest Expense.

Cash Position
Cash and cash equivalents increased by EUR 83 million vs. 2020. The year-end balance was EUR 89.4 million on December 31, 2021 vs. EUR 6.4 million on December 31, 2020.

Net cash used in operating activities was EUR 19.9 million vs. EUR 12.9 million in 2020. The increase was driven by the increase in the Operating Loss for the period.

The company invested EUR 2.3 million in assets in 2021, a EUR 2.2 million increase vs. 2020. The increase was driven primarily by IPO-related license fees paid and capitalized as intangible assets.

The Company successfully raised EUR 110 million through investing activities in 2021. EUR 80 million was raised via the IPO on Euronext Brussels and Euronext Amsterdam, preceded by a pre-IPO convertible note financing of EUR 30 million. The cash generated was offset by capitalized IPO fees paid in the amount of EUR 4.6 million. Net cash generated from financing activities was EUR 105.3 million in 2021 vs. EUR 4.4 in 2020.

Interest Bearing Loans
The decrease in Interest Bearing Loans from EUR 41.8 million in 2020 to EUR 11.5 million in 2021 was mainly attributable to the conversion of the Company’s preference A shares into ordinary shares immediately preceding the IPO.

The positive Equity position of the Company as of December 31, 2021 was EUR 82.7 million, an increase of EUR 114.8 million vs. December 31, 2020. This increase resulted from the proceeds from the IPO (EUR 80 million), the conversion of the convertible note into ordinary shares (EUR 31 million), the conversion of preference A shares into ordinary shares (EUR 34 million) and the accelerated vesting of the Employee Investment Plan (EUR 8.5 million). The increase was offset by the Net Loss for the period (EUR 34.3 million) and the total paid and unpaid capitalized IPO fees (EUR 4.9 million).

Q1 2022 Business Update and 2022 Outlook

The Company’s cash balance was EUR 83 million as of March 31, 2022, reflecting a cash burn of EUR 6.4 million during Q1 2022. This is in alignment with expectations that current cash on hand will fuel operations through the end of 2024.

In January, the Company was awarded 9 new patents in collaboration with leading research universities. The Company now has over 320 issued or pending patents worldwide.

In February, the Company’s technology was leveraged to enable people with the most severe form of spinal cord injuries to walk and stand again. This breakthrough was published in Nature Medicine and featured by media outlets around the globe.

In March, the Company enrolled the first participants in the LIFT Home Study, a trial designed to study the safety and performance of its ARCEX Therapy in the home setting.

In March, the Company was added to Euronext Brussels’ Bel-Small Index.

In March, the Company confirmed its cash runway through the end of 2024. The Company believes its strong cash position will mitigate the impact of global supply chain challenges that may affect certain development programs. At this time and barring unanticipated events, the Company believes it has mitigated the risk of further impacts to critical components.

In March, the Company added options to obtain rights to novel Brain-Spine Interface and Parkinson’s disease IP developed by its research partners at EPFL and Lausanne University Hospital (CHUV).

Building on progress shown in Q1, 2022, the Company expects to achieve several important milestones during the remainder of 2022:

  • Completion of the Up-LIFT Pivotal Study for the Company’s ARCEX Therapy
  • Release of top line data from the Up-LIFT Pivotal Study for the Company’s ARCEX Therapy
  • Completion of the LIFT Home Study for the Company’s ARCEX Therapy
  • Release of top line data from the LIFT Home Study for the Company’s ARCEX Therapy
  • First-in-human use of the Company’s ARCIM IPG
  • Commencement of the HeMon Feasibility Study for the Company’s ARCIM Therapy

“We demonstrated steady and consistent execution (and associated news flow) in Q1 2022”, said Dave Marver, CEO of ONWARD. “Our drive to execute will continue during the remainder of 2022, with several value-driving milestones expected, including top line data from the Company’s first pivotal trial and first-in-human use of our novel, proprietary, purpose-built neuromodulation platform.”

Conference Call & Webcast
ONWARD will host a conference call with live webcast today at 4 pm CET / 10 am ET. The webcast may be accessed on the Events page of the company’s website or by clicking here. A replay of the webcast will be available on the ONWARD website.

To learn more about ONWARD’s ARC Therapy and the company’s vision to restore movement, independence and health in people with spinal cord injury, please visit



ONWARD is a medical technology company creating innovative therapies to restore movement, independence, and health in people with spinal cord injury. ONWARD’s work builds on more than a decade of basic science and preclinical research conducted at the world’s leading neuroscience laboratories. ONWARD’s ARC Therapy, which can be delivered by implantable (ARCIM) or external (ARCEX) systems, is designed to deliver targeted, programmed stimulation of the spinal cord to restore movement and other functions in people with spinal cord injury, ultimately improving their quality of life. ONWARD has received three Breakthrough Device Designations from the FDA encompassing both ARCIM and ARCEX. The company’s first FDA pivotal trial, called Up-LIFT, completed enrollment in December 2021 with 65 subjects worldwide.

ONWARD is headquartered at the High Tech Campus in Eindhoven, the Netherlands. It maintains a significant team in Lausanne, Switzerland and has a growing U.S. presence in Boston, Massachusetts, USA. For additional information about the company, please visit To access our 2022 Financial Calendar, please visit

The Company is listed on Euronext Brussels and Euronext Amsterdam as of 21 October 2021 under the ONWD ticker with international securities identification number NL0015000HT4.


Certain statements, beliefs and opinions in this press release are forward-looking, which reflect the Company or, as appropriate, the Company directors’ current expectations and projections about future events. By their nature, forward-looking statements involve a number of risks, uncertainties and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward looking statements contained in this press release regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. As a result, the Company expressly disclaims any obligation or undertaking to release any update or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward-looking statements are based. Neither the Company nor its advisers or representatives nor any of its subsidiary undertakings or any such person’s officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.

To view this piece of content from, please give your consent at the top of this page.

Contact information

For Media Enquiries:
Simon Gentry- +44 (0) 7884 496 251

For Investor Enquiries:

For Company Enquiries:

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

flatexDEGIRO Offers Crypto Trading via Partnership With BISON (Boerse Stuttgart Group)19.5.2022 09:39:00 CEST | Press release

flatexDEGIRO AG (WKN: FTG111, ISIN: DE000FTG1111, Ticker: FTK.GR), Europe's largest and fastest growing retail online broker and Boerse Stuttgart Group, Europe's sixth largest exchange group, today announced the signing of a Memorandum of Understanding (MoU) on a partnership in crypto trading. This will give flatexDEGIRO customers direct access to trading in major cryptocurrencies via convenient and direct in-app access from flatex and DEGIRO with an accelerated onboarding process. For this purpose, Boerse Stuttgart Group provides its integrated offer in the crypto business, with uncomplicated trading via the retail platform BISON and use the secure crypto custody service operated by the custodian blocknox. The aim is to launch first at flatex Germany and Austria by the end of the third quarter of 2022, followed by the expansion of the offer to all DEGIRO customers. Frank Niehage, CEO of flatexDEGIRO: "As the European market leader in online stock trading, cryptocurrencies add a key el

Swiss Private Bank Selects Temenos to Digitally Transform Wealth Management Services19.5.2022 09:03:00 CEST | Press release

Temenos (SIX: TEMN), the cloud banking platform, today announced that Mirabaud, the Swiss private bank, has selected Temenos to move from a traditional on-premise system to a digital end-to-end wealth management platform on Temenos Banking Cloud. With the generational transfer of wealth, new regulations and growth in asset classes such as private equity and digital assets, Temenos Banking Cloud gives Mirabaud the agility to quickly adapt to changing investment opportunities and client expectations. Mirabaud will adopt the complete suite of Temenos wealth banking capabilities, from self-service channels and portfolio management to back-office processing, including Payments, Financial Crime Mitigation and Data Lake. The breadth and depth of Temenos wealth capabilities will enable Mirabaud to deliver a digital customer experience with personalized services and highly automated processes. Privacy is and will always remain an absolute key consideration for Mirabaud in selecting its business

Suzano records a landmark 2021 with publication of Annual Report19.5.2022 09:00:00 CEST | Press release

Suzano, one of the world’s largest integrated pulp and paper producers, announces the publication of its 2021 Annual Report and the launch of a revitalized Sustainability Center. Despite the pandemic impacting daily lives and work routines, Suzano was able to deliver the strongest financial results in its history and make significant progress on strategically important developments for the business. Furthermore, 2021 has represented a landmark year for Suzano towards achieving its 15 long-term 2030 sustainability goals, known as the Commitments to Renewing Life. Key highlights across the year include: Record financial performance Net sales increase of 34% Adjusted EBITDA increase of 57% Net Income of R$ 8.6bn Combined successful issue of US$ 1.5bn of sustainability-linked bonds Landmark developments Launched the Cerrado Project, the largest single line pulp mill in the world, which will be fully operational in 2024 Established a joint venture with Spinnova to exclusively produce 100% r

stc pay Scales to 8 Million Accounts on Temenos Open Platform19.5.2022 08:27:00 CEST | Press release

Temenos (SIX: TEMN) today announced that stc pay, the Middle East’s leading digital wallet, is live on Temenos open platform for composable banking. Temenos’ cloud-native platform has supported stc pay to scale efficiently to more than 8 million accounts. stc pay makes it easy for customers to manage money on their smartphone, send and receive payments from anywhere around the globe, shop online and withdraw funds from ATMs. Launched in 2018 as an Electronic Money Institution (EMI), stc pay received a digital banking license from Saudi Central Bank in 2021. stc pay can now leverage Temenos open platform for composable banking to capture new opportunities with future products. stc pay runs entirely on Temenos open platform using Temenos Banking Capabilities to handle all transactions and processing for Customer Accounts. The advanced technology architecture provides the most open and secure cloud-native platform for stc pay to compose, extend and deploy banking capabilities at scale. st

Lineage Opens Latest Fully-Automated Cold-Storage Warehouse Expansion in Peterborough to Create South East Superhub19.5.2022 08:00:00 CEST | Press release

Lineage Logistics, LLC (“Lineage” or the “Company”), one of the world’s leading temperature-controlled industrial REIT and logistics solutions providers, today unveiled its South East Superhub in Peterborough, Cambridgeshire, just 70 miles from Central London and 120 miles from its Northern Superhub in Heywood near Manchester. Lineage completed the new, fully-automated warehouse expansion with an additional 45,000 pallet positions in Peterborough, bringing the total capacity to nearly 71,000 pallets today. The expanded warehouse creates a strategically-positioned South East Superhub, which will serve both retail and foodservice customers with unique supply chain requirements. This 35-metre tall expansion will feature some of the world’s most sophisticated automation and refrigeration technology, helping to reduce energy consumption and the environmental impact of food distribution. “We are investing in the future of food supply chain across Europe, using the latest technology, data ana